Morgan Stanley has increased its price target for Cardinal Health (CAH) to $255 from $245, maintaining an Overweight rating. This revision follows the company’s strong Q2 results. Other firms like Baird, UBS, Evercore ISI, and Mizuho have also recently raised their price targets for Cardinal Health.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cardinal Health price target raised to $255 from $245 at Morgan Stanley
Morgan Stanley has increased its price target for Cardinal Health (CAH) to $255 from $245, maintaining an Overweight rating. This revision follows the company’s strong Q2 results. Other firms like Baird, UBS, Evercore ISI, and Mizuho have also recently raised their price targets for Cardinal Health.